Faculty Profiles - KAWAI Hotaka

MISC - KAWAI Hotaka

Division display 81 - 92 of about 92 ／ All the affair displays >>

口腔扁平上皮癌における1p36領域のLOH解析およびRIZ1発現の検討

玉村亮, 岡田裕之, 武部祐一郎, 河合穂高, 辻極秀次, 長塚仁

日本病理学会会誌 103 ( 1 ) 282 - 282 2014.3

エナメル上皮腫におけるCCN2の発現解析

河合穂高, 武部祐一郎, 片瀬直樹, 于淞, 藤井昌江, 高畠清文, 辻極秀次, 長塚仁

日本病理学会会誌 103 ( 1 ) 308 - 308 2014.3

硬組織形成過程における細胞外微小環境としてのハニカムβ-TCP

辻極秀次, 伊藤聡, 片瀬直樹, 玉村亮, 于淞, 李海テイ, 武部祐一郎, 河合穂高, 長塚仁

日本口腔科学会雑誌 63 ( 1 ) 100 - 100 2014.1

DKK3の頭頸部扁平上皮癌における発現の検討

藤井昌江, 片瀬直樹, 高畠清文, 武部祐一郎, YU Song, 河合穂高, 辻極秀次, 長塚仁

日本臨床口腔病理学会総会・学術大会プログラム・抄録集 25th 122 2014

ハニカムβ-TCPを用いた細胞外微小環境再現による硬組織再生

高畠清文, 辻極秀次, 武部祐一郎, 藤井昌江, 河合穂高, 于淞, 長塚仁

Journal of Oral Biosciences Supplement (Web) 2014 2014

骨治癒過程における骨髄由来細胞の関与

河合穂高, 辻極秀次, 伊藤聡, 中野敬介, 于淞, 川上敏行, 長塚仁

Journal of Oral Biosciences Supplement 2013 120 - 120 2013.9

頭頸部扁平上皮癌におけるDkk-3の免疫組織化学的検討

藤井昌江, 伊藤聡, 于淞, 武部祐一郎, 河合穂高, 辻極秀次, 長塚仁

Journal of Oral Biosciences Supplement 2013 115 - 115 2013.9

エナメル上皮腫におけるCCN2の発現と間質線維芽細胞への作用について

武部祐一郎, 辻極秀次, 于淞, 藤井昌江, 河合穂高, 玉村亮, 佐々木朗, 長塚仁

Journal of Oral Biosciences Supplement 2013 165 - 165 2013.9

腫瘍の微小環境形成に関与する骨髄由来細胞の動態について

玉村亮, 武部祐一郎, 片瀬直樹, 河合穂高, 辻極秀次, 長塚仁

日本病理学会会誌 102 ( 1 ) 437 - 437 2013.4

Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: A multicenter, retrospective analysis in Japan

Katsuyoshi Takata, Hiroyuki Okada, Naoki Ohmiya, Shotaro Nakamura, Yasuhiko Kitadai, Akira Tari, Taiji Akamatsu, Hiroki Kawai, Shu Tanaka, Hiroshi Araki, Takashi Yoshida, Hirokazu Okumura, Hogara Nishisaki, Tamotsu Sagawa, Norihiko Watanabe, Nobuyoshi Arima, Noritaka Takatsu, Masanao Nakamura, Shunichi Yanai, Hiroyasu Kaya, Toshiaki Morito, Yasuharu Sato, Hisataka Moriwaki, Choitsu Sakamoto, Yasumasa Niwa, Hidemi Goto, Tsutomu Chiba, Takayuki Matsumoto, Daisuke Ennishi, Tomohiro Kinoshita, Tadashi Yoshino

CANCER SCIENCE 102 ( 8 ) 1532 - 1536 2011

Language：English Publisher：WILEY

We conducted a multicenter, retrospective study to determine the anatomical distribution and prognostic factors of gastrointestinal (GI) follicular lymphoma (FL). This study included 125 patients with stage I and II1 GI-FL. Of the 125 patients, the small intestine was examined in 70 patients, with double-balloon endoscopy and/or capsule endoscopy. The most frequently involved GI-FL site was the duodenal second portion (DSP) (81%), followed by the jejunum (40%); 85% of patients with involvement of the DSP also had jejunal or ileal lesions. The absence of abdominal symptoms and macroscopic appearance of multiple nodules were significantly present in the DSP-positive group. During a median follow up of 40 months, six patients showed disease progression. Patients with involvement of the DSP had better progression-free survival (PFS) than those without such involvement (P = 0.001). A multivariate analysis revealed that male sex, the presence of abdominal symptoms, and negative involvement of the DSP were independently associated with poor PFS. In conclusion, most patients with GI-FL have duodenal lesions associated with multiple jejunal or ileal lesions. Gastrointestinal follicular lymphomas involving the DSP might be a distinct entity showing a favorable clinical course. (Cancer Sci 2011; 102: 1532-1536)

DOI： 10.1111/j.1349-7006.2011.01980.x

Web of Science

researchmap

Promotion of bone regeneration by CCN2 incorporated into gelatin hydrogel. International journal

Takeshi Kikuchi, Satoshi Kubota, Koji Asaumi, Harumi Kawaki, Takashi Nishida, Kazumi Kawata, Shigeru Mitani, Yasuhiko Tabata, Toshifumi Ozaki, Masaharu Takigawa

Tissue engineering. Part A 14 ( 6 ) 1089 - 1098 2008

Language：English

CCN family protein 2/connective tissue growth factor (CCN2/CTGF) is a unique molecule that promotes the entire endochondral ossification process and regeneration of damaged articular cartilage. Also, CCN2 has been shown to enhance the adhesion and migration of bone marrow stromal cells as well as the growth and differentiation of osteoblasts; hence, its utility in bone regeneration has been suggested. Here, we evaluated the effect of CCN2 on the regeneration of an intractable bone defect in a rat model. First, we prepared two recombinant CCN2s of different origins, and the one showing the stronger effect on osteoblasts in vitro was selected for further evaluation, based on the result of an in vitro bioassay. Next, to obtain a sustained effect, the recombinant CCN2 was incorporated into gelatin hydrogel that enabled the gradual release of the factor. Evaluation in vivo indicated that CCN2 continued to be released at least for up to 14 days after its incorporation. Application of the gelatin hydrogel-CCN2 complex, together with a collagen scaffold to the bone defect prepared in a rat femur resulted in remarkable induction of osteoblastic mineralization markers within 2 weeks. Finally, distinct enhancement of bone regeneration was observed 3 weeks after the application of the complex. These results confirm the utility of CCN2 in the regeneration of intractable bone defects in vivo when the factor is incorporated into gelatin hydrogel.

DOI： 10.1089/ten.tea.2007.0167

PubMed

researchmap

Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy

Hotaka Kawai, K Kiura, M Tabata, T Yoshino, Takata, I, A Hiraki, K Chikamori, H Ueoka, M Tanimoto, M Harada

LUNG CANCER 35 ( 3 ) 305 - 314 2002.3

Language：English Publisher：ELSEVIER SCI IRELAND LTD

We established several in vitro drug-resistant cell lines after continuous, long-term exposure of each drug to elucidate mechanisms of drug resistance. Whether drug resistance in these in vitro resistant cell lines reflects clinical drug resistance still remains unanswered. In this study, a pair of lung cancer cell lines was established from one patient with squamous cell carcinoma of the lung, with one line being established before and one line after combination chemotherapy (cisplatin/ifosfamide/vindesine). Combination chemotherapy selected resistant EBC-2/R cells, which showed cross-resistance to 4-hydroxyifosfamide (3.2-fold), cisplatin (2.3-fold), and methotrexate (3.7-fold) and collateral sensitivity to vindesine (0.77-fold) compared with parent EBC-2 cells. EBC-2/R cells showed decrease in intracellular accumulation of cisplatin, increase in intracellular concentration of glutathione (GSH), and overexpression of multidrug resistance-associated protein (MRP) 3 when compared with EBC-2 cells. A single cycle of chemotherapy was not sufficient to select other mechanisms of drug resistance, such as multidrug resistance-1/P-glycoprotein, MRPs 1, 2, 4, and 5, lung resistance-related protein, metallothionein IIa, glutathione S-transferase pi, gamma-glutamyleysteine synthetase (light and heavy chain), and excision repair cross complementing 1. Sequentially we established two cell lines, which cell lines showed the differences of the cisplatin resistance, expression level of MRP3, intracellular GSH level and intracellular accumulation of cisplatin. A pair of cell lines will be useful to elucidate resistant mechanisms of cisplatin in heterogeneous lung cancer cells. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

DOI： 10.1016/S0169-5002(01)00430-5

Web of Science

researchmap

　 PREV - NEXT 　

< KAWAI Hotaka >

MISC - KAWAI Hotaka